July 11, 2025

Delayed Breast Cancer Care Triples Death Risk

Delays longer than 90 days before seeking care for breast cancer were linked to a threefold increase in two-year mortality, particularly affecting older and socially isolated patients, according to a multicenter Spanish study.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 24, 2025

X-ray Telescopes Detect Elusive “Missing” Intergalactic Matter

ESA and JAXA missions map faint X-ray emission across 23-million-light-year structure linking four galaxy clusters

The Analytical Scientist

June 19, 2025

AI Models Predict Lung Cancer Risk Better

A new review finds AI-based models more accurate than traditional regression models at predicting lung cancer risk, especially when using low-dose CT imaging data.

Conexiant

June 19, 2025

AI Models Predict Lung Cancer Risk Better

A new review finds AI-based models more accurate than traditional regression models at predicting lung cancer risk, especially when using low-dose CT imaging data.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

June 06, 2025

Lower-Dose Treatment Effective in Anal Cancer Trial, Study

In a recent clinical trial, researchers found that a reduced-dose chemoradiotherapy regimen for early-stage anal cancer may be comparable to standard treatment in achieving short-term tumor response, while causing fewer serious side effects.

Conexiant

April 24, 2025

Vitamin D Multifaceted CRC Immunomodulator Revealed

"Vitamin D enhances immune organ functions such as the spleen and lymph nodes, and boosts T-cell activity, which is essential in defending the body against tumors."

Conexiant

April 25, 2025

FDA Approves Penpulimab-kcqx for NPC

The FDA approved penpulimab-kcqx for first line and previously treated recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.

Conexiant